Dual immunotherapy and chemotherapy prove beneficial for specific subgroup of lung cancer patients
Immunogenomic correlates and clinical outcomes with PCP chemoimmunotherapy in patients with STK11 and/or KEAP1 mutant advanced NSCLC. Credit: Nature (2024). ...
